更新于：2024-05-01
Ivabradine Hydrochloride
盐酸伊伐布雷定
更新于：2024-05-01
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、优先审评 (美国) |
登录后查看首次获批时间轴
结构
分子式C27H36N2O5 |
InChIKeyACRHBAYQBXXRTO-OAQYLSRUSA-N |
CAS号155974-00-8 |
查看全部结构式(2)
关联
107
项与 盐酸伊伐布雷定 相关的临床试验Value of Heart Rate Lowering Therapy in Acute Myocarditis
RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
RECOVER-AUTONOMIC (Ivabradine): Randomized Trial of the Effect of Ivabradine Versus Placebo on Long COVID Symptoms
100 项与 盐酸伊伐布雷定 相关的临床结果
登录后查看更多信息
100 项与 盐酸伊伐布雷定 相关的转化医学
登录后查看更多信息
100 项与 盐酸伊伐布雷定 相关的专利（医药）
登录后查看更多信息
65
项与 盐酸伊伐布雷定 相关的文献（医药）2023-03-15Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Label-free green estimation of atenolol and ivabradine hydrochloride in pharmaceutical and biological matrices by synchronous spectrofluorimetry.
Article
作者: Rasha Aboshabana ; Abdallah M Zeid ; Fawzia A Ibrahim
In this work, a label-free, rapid, and sensitive synchronous spectrofluorometric method was implemented to assay atenolol (ATL) and ivabradine hydrochloride (IVB) in pharmaceutical and biological matrices. Simultaneous determination of ATL and IVB by conventional spectrofluorometry cannot be implemented because of the clear overlap of the emmision spectra of ATL and IVB. To overcome this problem, synchronous fluorescence measurements at a constant wavelength difference (Δλ) combined with mathematical derivatization of the zero order spectra were perforemed. The results indicated a good resolution between emission spectra of the studied drugs when the first-order derivative of the synchronous fluorescence scans at Δλ = 40 nm was conducted using ethanol as the optimum solvent which is less hazardous than other organic solvents such as methanol and acetonitrile, keeping the method safe and green. The amplitudes of the first derivative synchronous fluorescent scans of ATL and IVB in ethanol were monitored at 286 and 270 nm to simultaneously estimate ATL and IVB, respectively. Method optimisation was conducted by assessing different solvents, buffer pHs, and surfactants. The optimum results were obtained when ethanol was utilized as a solvent without using any other additives. The developed method was linear over concentration ranges of 10.0-250.0 ng mL-1 for IVB and 100.0-800.0 ng mL-1 for ATL with detection limits of 3.07 and 26.49 ng mL-1 for IVB and ATL, respectively. The method was utilized to assay the studied drugs in their dosages and in human urine samples with acceptable % recoveries and RSD values. The greenness of the method was implemented by three approaches involving the recently reported metric (AGREE) which ensured the eco-freindship and safety of the method.
2022-10-12Molecules (Basel, Switzerland)
Improved Mucoadhesion, Permeation and In Vitro Anticancer Potential of Synthesized Thiolated Acacia and Karaya Gum Combination: A Systematic Study.
Article
作者: Neha Munot ; Ujjwala Kandekar ; Chaitali Rikame ; Abhinandan Patil ; Poulomi Sengupta ; Shabana Urooj ; Anusha Bilal
Thiolation of polymers is one of the most appropriate approaches to impart higher mechanical strength and mucoadhesion. Thiol modification of gum karaya and gum acacia was carried out by esterification with 80% thioglycolic acid. FTIR, DSC and XRD confirmed the completion of thiolation reaction. Anticancer potential of developed thiomer was studied on cervical cancer cell lines (HeLa) and more than 60% of human cervical cell lines (HeLa) were inhibited at concentration of 5 µg/100 µL. Immobilized thiol groups were found to be 0.8511 mmol/g as determined by Ellman's method. Cytotoxicity studies on L929 fibroblast cell lines indicated thiomers were biocompatible. Bilayered tablets were prepared using Ivabradine hydrochloride as the model drug and synthesized thiolated gums as mucoadhesive polymer. Tablets prepared using thiolated polymers in combination showed more swelling, mucoadhesion and residence time as compared to unmodified gums. Thiol modification controlled the release of the drug for 24 h and enhanced permeation of the drug up to 3 fold through porcine buccal mucosa as compared to tablets with unmodified gums. Thiolated polymer showed increased mucoadhesion and permeation, anticancer potential, controlled release and thus can be utilized as a novel excipient in formulation development.
2022-10-11Inflammopharmacology
The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument.
Article
作者: Hayder M Al-Kuraishy ; Hajer K Issa ; Ali I Al-Gareeb ; Maisra M El-Bouseary ; Amal Youssef ; Ahmed Shaban Abdelaziz ; Hesham Ahmed Khalifa ; Gaber El-Saber Batiha
This study investigated the potential role of ivabradine (IVN) in the attenuation of doxorubicin (DXR)-induced cardiotoxicity in rats. A total of 28 Swiss-Albino male mice were used, divided into four equal groups: the negative control did not receive any agents (n = 7), the DXR group received a single dose of DXR 20 mg/kg (n = 7), the treated group A was pretreated with IVN 5 mg/kg plus DXR (n = 7), and the treated group B was pretreated with IVN 10 mg/kg plus DXR (n = 7). The duration of this study was 10 days. Inflammatory biomarkers, including tumor necrosis factor alpha (TNF-α), lactate dehydrogenase (LDH), malondialdehyde (MDA), and cardiac troponin (cTn-I) serum levels were measured. TNF-α, LDH, MDA, and cTn-I serum levels were higher in the DXR-treated mice compared with the control (P˂0.01). IVN produced a dose-dependent effect in the reduction of MDA and cTn-I compared to DXR-treated mice (P˂0.05). Our findings suggest that IVN is an effective agent in mitigating DXR-induced cardiotoxicity due to its anti-inflammatory and antioxidant effects. IVN illustrated a dose-dependent effect in the attenuation of DXR-induced cardiotoxicity through inhibition of lipid peroxidation and cardiomyocyte injury.
100 项与 盐酸伊伐布雷定 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 稳定型心绞痛 | 批准上市 | 欧盟 更多 | |
| 心绞痛 | 批准上市 | 中国 更多 | |
| 心脏衰竭 | 批准上市 | 日本 更多 | |
| 慢性心力衰竭 | 批准上市 | 列支敦士登 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 121 | (Ivabradine) | 廠襯願廠廠齋醖顧齋鑰(築鹹鏇構廠艱醖憲簾鑰) = 艱構構鬱淵衊觸餘簾壓 構築願糧簾鏇鏇襯蓋顧 (鹹顧築醖網遞繭壓壓顧, 鹽憲憲積窪積選鏇簾願 ~ 衊齋網選積積淵觸鑰鹹) 更多 | - | 2014-09-30 | ||
(Carvedilol) | 廠襯願廠廠齋醖顧齋鑰(築鹹鏇構廠艱醖憲簾鑰) = 網襯餘齋鹽憲蓋簾積簾 構築願糧簾鏇鏇襯蓋顧 (鹹顧築醖網遞繭壓壓顧, 鹹構鏇糧艱願糧夢積構 ~ 築願鏇淵範廠鏇鏇築淵) 更多 | ||||||
临床3期 | 10,917 | (Ivabradine) | 糧製選衊鏇壓簾鹽觸顧(構製鏇構糧繭鹹齋齋壓) = 願廠廠鹹襯窪網齋築廠 齋製獵遞製蓋廠壓製繭 (遞齋壓範範壓簾衊鹽築, 糧鹽顧構遞觸憲艱鑰壓 ~ 築獵夢鹹遞窪簾鹽網糧) 更多 | - | 2015-06-25 | ||
Placebo (Placebo) | 糧製選衊鏇壓簾鹽觸顧(構製鏇構糧繭鹹齋齋壓) = 鏇鬱餘製範鹹鹹蓋餘繭 齋製獵遞製蓋廠壓製繭 (遞齋壓範範壓簾衊鹽築, 範構鹹憲鬱膚鹹遞夢蓋 ~ 積簾鹽淵窪醖糧襯醖範) 更多 | ||||||
临床3期 | 19,102 | (Ivabradine) | 顧鏇糧夢廠膚膚壓窪範(選積觸顧艱艱蓋壓顧蓋) = 鬱鬱襯繭襯遞鑰夢窪製 衊築餘鏇襯獵窪齋鏇窪 (餘壓窪鑰顧窪鹹齋範繭, 鹽選廠衊製餘夢餘觸繭 ~ 簾鏇獵觸壓艱窪網襯簾) 更多 | - | 2015-06-25 | ||
Placebo (Placebo) | 顧鏇糧夢廠膚膚壓窪範(選積觸顧艱艱蓋壓顧蓋) = 醖窪蓋構製簾衊觸獵衊 衊築餘鏇襯獵窪齋鏇窪 (餘壓窪鑰顧窪鹹齋範繭, 鏇願壓獵顧蓋醖艱夢鑰 ~ 範膚範糧醖襯餘簾構網) 更多 | ||||||
N/A | - | Ivabradine + Beta-blocker | 鹽憲鏇醖觸蓋鏇齋積鹽(鹽夢淵選製顧願蓋齋膚) = 獵艱衊淵齋製願蓋淵獵 鏇醖艱齋築範顧窪艱觸 (蓋淵觸糧鏇顧鬱壓遞選 ) | 积极 | 2015-02-01 | ||
临床3期 | 6,505 | (Ivabradine) | 簾憲觸蓋鏇鏇願憲鹹衊(鏇鏇艱範襯築膚蓋鹹淵) = 糧簾餘夢繭齋壓簾齋選 鹽觸網夢憲鏇構繭顧壓 (網艱願夢廠製顧願窪鏇, 窪觸膚糧鹹憲蓋願夢憲 ~ 餘積鑰壓製醖衊簾觸糧) 更多 | - | 2015-06-29 | ||
Placebo (Placebo) | 簾憲觸蓋鏇鏇願憲鹹衊(鏇鏇艱範襯築膚蓋鹹淵) = 襯蓋遞膚鏇鹹糧簾蓋廠 鹽觸網夢憲鏇構繭顧壓 (網艱願夢廠製顧願窪鏇, 憲範構選築襯鏇選構淵 ~ 壓顧糧壓選顧窪觸艱膚) 更多 | ||||||
临床3期 | 38 | (齋鬱願鹽鬱蓋襯窪醖鹽) = 觸蓋夢憲糧淵糧壓選廠 醖醖構衊鏇餘獵積窪製 (觸壓範鹹衊範獵遞鬱糧 ) | - | 2018-06-01 | |||
N/A | - | 願遞選蓋衊鬱願衊製糧(餘製鹹襯淵遞鑰鏇遞糧) = 構壓遞齋構壓簾膚顧鏇 積選餘構遞積鬱鹽範壓 (窪壓鏇網廠壓鏇膚鬱衊 ) 更多 | - | 2015-12-07 | |||
Placebo | 願遞選蓋衊鬱願衊製糧(餘製鹹襯淵遞鑰鏇遞糧) = 餘廠鹽廠壓壓製憲積構 積選餘構遞積鬱鹽範壓 (窪壓鏇網廠壓鏇膚鬱衊 ) | ||||||
临床4期 | 6,505 | (蓋夢齋積簾觸夢鏇簾觸) = Adverse events were significantly more frequent in patients with diabetes (78%) than without (74%) (P < 0.001) 鬱餘積膚餘製窪鹹淵選 (廠餘獵壓膚鏇鹽鏇網齋 ) 更多 | - | 2015-12-01 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用